Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides

Article metrics

Abstract

The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity. To probe the mechanism of these associations, cell lines were created which secrete each apoE isoform. ApoE conditioned media, purified apoE, and commercially obtained apoE protected B12 cells from hydrogen peroxide cytotoxicity with E2 > E3 > E4. Physiological levels of apoE protected cells from β–amyloid peptides, while higher doses of apoE led to increased cytotoxicity. E2 > E3 > E4 possessed antioxidant activity, and apoE bound certain metal ions. The decreased antioxidant activity of E4 could contribute to its association with Alzheimer's disease, cardiovascular disease and decreased longevity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Corder, E.H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921–923 (1993).

  2. 2

    Mayeux, R. et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann. Neurol. 34, 752–754 (1993).

  3. 3

    van Duijin, C.M. et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nature Genetics 7, 74–78 (1994).

  4. 4

    Hendrie, H.C. et al. Apolipoprotein E genotypes and AD in a community study of elderly African Americans. Ann. Neurol. 37, 118–120 (1995).

  5. 5

    Saunders, A.M. et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467–1472 (1993).

  6. 6

    Corder, E.H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7, 180–184 (1994).

  7. 7

    Maestre, G. et al. Apolipoprotein E and Alzheimer’s disease: ethnic variation in genotypic risks. Ann. Neurol. 37, 254–259 (1995).

  8. 8

    Xhignesse, M., Lussier-Cacan, S., Sing, C.F., Kessling, A.M. & Davignon, J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler. Thromb. 11, 1100–1110 (1991).

  9. 9

    Stengard, J.H. et al. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91, 265–269 (1995).

  10. 10

    van Bockxmeer, F.M., Mamotte, C.D., Gibbons, F.R. & Taylor, R.R. Apolipoprotein epsilon 4 homozygosity — a determinant of restenosis after coronary angioplasty. Atheroscler. 110, 195–202 (1994).

  11. 11

    Schachter, F. et al. Genetic associations with human longevity at the apoE and ACE loci. Nature Genet. 6, 29–32 (1994).

  12. 12

    Louhija, J. et al. Aging and genetic variation of plasma apolipoproteins. Arterioscler. Thromb. 14, 1084–1089 (1994).

  13. 13

    Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).

  14. 14

    Pike, C.J., Burdick, D., Walencewicz, A.J., Gabe, C.G. & Cotman, C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676–1687 (1993).

  15. 15

    Behl, C., Davis, J., Cole, G.M. & Schubert, D. Vitamin E protects nerve cells from amyloid βprotein toxicity. Biochem. Biophys. Res. Comm. 186, 944–950 (1992).

  16. 16

    Behl, C., Davis, J., Lesley, R. & Schubert, D. Hydrogen peroxide mediates amyloid βprotein toxicity. Cell 77, 817–827 (1994).

  17. 17

    Butterfield, D.A., Hensley, K., Harris, M., Mattson, M. & Carney, J. β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Comm. 200, 710–715 (1994).

  18. 18

    Wisniewski, T. & Frangione, B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett 135, 235–238 (1992).

  19. 19

    Sanan, D.A. et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J. Clin. Invest. 94, 860–869 (1994).

  20. 20

    Ma, J., Yee, A., Brewer, H.B., Das, S. & Potter, H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92–94 (1994).

  21. 21

    Nathan, B.P. et al. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 264, 850–852 (1994).

  22. 22

    Hartmann, H., Eckert, A. & Muller, W.E. Apolipoprotein E and cholesterol affect neuronal calcium signaling: the possible relationship between β-amyloid and neurotoxicity. Biochem. Biophys. Res. Comm. 200, 1185–1192 (1994).

  23. 23

    Strittmater, W.J. et al. Isoform-specific interactions of apolipoprotein E with microtubule associated protein tau: Implications for Alzheimer disease. Proc. Natl. Acad Sci. U. S. A. 91, 11183–11186 (1994).

  24. 24

    Hayek, T., Oikinine, J., Brook, J.G. & Avriam, M. Increased plasma and lipoprotein lipid peroxidation in apolipoprotein E deficient mice. Biochem Biophys. Res. Comm. 201, 1567–1574 (1994).

  25. 25

    Rinninger, F. & Pittman, R.C. Mechanism of the cholesteryl ester transfer protein-mediated uptake of high density lipoprotein cholesteryl esters by Hep G2 cells. J. Biol. Chem. 264, 6111–6118 (1989).

  26. 26

    Jaeckle, S., Brady, S.E. & Havel, R.J. Membrane binding sites for plasma lipoproteins on endosomes from rat liver. Proc. Natl. Acad. Sci. U.S.A. 86, 1880–1884 (1989).

  27. 27

    Weisgraber, K.H., Innerarity, T.L. & Mahley, R.W. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J. Biol. Chem. 253, 9053–9062 (1978).

  28. 28

    Maxwell, S.J.R., Wiklund, O. & Bondjers, G. Measurement of antioxidant activity in lipoproteins using enhanced chemiluminescence. Atheroscler. 111, 79–89 (1994).

  29. 29

    Dong, L.M. et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269, 22358–22365 (1994).

  30. 30

    Schaefer, E.J. et al. Familial apolipoprotein E deficiency. J. Clin. Invest. 78, 1206–1219 (1986).

  31. 31

    Plump, A.S. et al. Severe hypercholesterolaemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353 (1992).

  32. 32

    Lehtimaki, T. et al. Apolipoprotein E polymorphism and its influence on apoE concentrations in cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95, 39–42 (1995).

  33. 33

    Burdick, D. et al. Assembly and aggregation properties of synthetic Alzheimer's A/4β amyloid peptide analogs. J. Biol. Chem. 267, 546–554 (1992).

  34. 34

    Strittmatter, W.J. et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 8098–8102 (1993).

  35. 35

    Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J. & Frangione, B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Comm. 192, 359–365 (1993).

  36. 36

    Evans, K.C., Berger, E.P., Cho, C.-G., Weisgraber, K.H. & Lansbury, P.T.J. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 92, 763–767 (1995).

  37. 37

    LaDu, M.J. et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23403–23406 (1994).

  38. 38

    LaDu, M.J. et al. Purification of apoE attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270, 9039–9042 (1995).

  39. 39

    Whitson, J.S. et al. Attenuation of the neurotoxic effect of β amyloid by apolipoprotein E. Biochem. Biophys. Res. Comm. 199, 163–170 (1994).

  40. 40

    Buettner, G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535–543 (1993).

  41. 41

    Kunitake, S.T., Jarvis, M.R., Hamilton, R.L. & Kane, J.P. Binding of transition metals by apolipoprotein A-l-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 89, 6993–6997 (1992).

  42. 42

    Ehrenwald, E., Chisolm, G.M. & Fox, P.L. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest. 93, 1493–1501 (1994).

  43. 43

    Mantyh, P.W. et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J. Neurochem. 61, 1171–1174 (1993).

  44. 44

    Regan, L. Protein design: novel metal-binding sites. Trends Biochem. Sci. 20, 280–285 (1995).

  45. 45

    Smith, J.D., Melian, A., Leff, T. & Breslow, J.L. Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements. J. Biol. Chem. 263, 8300–8308 (1988).

  46. 46

    Buege, J.A. & Aust, S.D. Microsomal lipid peroxidation. Meth. Enzymol. 52, 302–310 (1978).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading